Gsk Share Discussion Threads

[gateside] 12/2/2022 11:26

Pierre - It's amazing how often that question is asked!

[pierre oreilly] 12/2/2022 10:58

Rofl net, after your 30 years investing, i know you know the answer! You can't day trade without knowing that.

Or maybe i'm wrong and traders don't know - that would explain partly why 80% of them lose everything!

[netcurtains] 12/2/2022 10:50

Question:
GSK says it goes Ex-Dividend on 2022-02-24.

Does that mean if I buy shares on Wednesday 2022-02-23 and hold them for a couple of days I get the dividend?

Thanks

[pander45] 11/2/2022 19:52

I usually ignore the colour and look at the chart behaviour at the strike point of the trade. Usually tells the story.

[spoole5] 11/2/2022 13:57

Looks like ULVR came off best in the end!

[pander45] 11/2/2022 13:16

I would say a sell.

[garycook] 11/2/2022 12:39

Any comment on this purchase at 12.09 5347 1617.6 5181585 O

[pander45] 11/2/2022 11:16

Bad day at the office here so far

[charlie9038] 11/2/2022 10:28

Spoole5 on the shorts

[spoole5] 11/2/2022 09:17

Going to take a very long time to achieve the value that was on the table a couple of weeks ago. We'll done Emma.

[jonjoneil] 11/2/2022 09:14

WARNING! - Holding Glaxo stock can be bad for your health :--)

[spoole5] 11/2/2022 08:11

Sub 16 here soon whilst AZN marches on.

[zho] 11/2/2022 08:09

As ever, though, investors look ahead. Seven potential drugs, including biggies for a respiratory virus, hepatitis B and rheumatoid arthritis, receive critical read-outs from the labs this year, the first big test on Walmsley’s watch of the quality of the pipeline. Further out, she may need a big pharma deal to ignite the next round of innovation – or, at least, that’s the City’s view. But she’s in the hunt. Her position looks as secure now as at any time in the past year.

[spoole5] 11/2/2022 08:04

That's the divi gone already!

[jonjoneil] 10/2/2022 15:46

TM
This is very good news but nothing to do with Hal. It was introduced in 2011.

[tradermichael] 10/2/2022 15:28

Here's the next big one for Hal:

GlaxoSmithKline PLC said Thursday that China's National Medical Products Administration has approved its Benlysta product, for treatment of adult patients with active lupus nephritis who are receiving standard of care.

The pharmaceutical giant said that the approval extends the current indication in China for the drug to be used as an add-on therapy in adults and children of five-years and older with active systemic lupus erythematosus, an autoimmune disease.

The approval makes Benlysta the first and only biologic approved in China for both systemic lupus erythematosus, and lupus nephritis, caused by SLE. The product can help preserve kidneys and allow for a reduction in doses of steroids and immunosuppressants that would otherwise be used, which can have toxic side effects.

Nearly half a million people in China have SLE, and more than half of these will develop lupus nephritis.

"Recognizing that lupus nephritis can lead to kidney damage, this approval will allow patients in China access to a new treatment option to help slow the progressive nature of systemic lupus," Chief Scientific Officer and Research and Development President Hal Barron said.

[spoole5] 10/2/2022 13:30

GSK is nowhere near AZN, of course that may well change if the pipeline is as strong as they say

[jonjoneil] 10/2/2022 12:43

TM
That wasn't a good comparison.
Bottom line - AZN make good decisions, GSK don't. I doubt they would have given Hal a job!

[our haven] 10/2/2022 12:19

TraderMichael. Yes really. That's how they have raised their dividend and their outlook.Currently 3 percent rise in the share price with the good news.

[tradermichael] 10/2/2022 10:12

Really?

AZN's annual results showed that despite a 38% rise in revenue, AZ swung from pre-tax profits of almost £3bn in 2020 to a bottom line loss of £196m.
It reflected, the company said, its £29bn takeover of US-based Alexion Pharmaceuticals, and the costs of new drug research.

[waldo2020] 10/2/2022 08:44

Indeed spoole5....I hope Emma's taking note!

[spoole5] 10/2/2022 08:23

AZN showing how it's really done again!

[patientcapital] 10/2/2022 08:03

Unilever clearly needed a distraction.

[tradermichael] 10/2/2022 07:33

Coco - and will you do the same with the CH shares after the 'split'?